News & Updates

New drug applications approved by US FDA as of 16-30 September 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Cytological analysis of voided urine and vaginal fluid has good accuracy for detecting endometrial cancer in women with postmenopausal bleeding, as shown in the DETECT trial.

Use of aspirin after curative-intent treatment of colorectal cancer (CRC) liver metastases does not appear to improve disease-free survival and is even associated with reduced overall survival and more serious adverse events (AEs), according to the phase III ASAC trial

New drug applications approved by US FDA as of 1-15 September 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with the anti-epidermal growth factor receptor antibody-drug conjugate becotatug vedotin, compared with chemotherapy, results in significant improvements in objective response rate (ORR) and progression-free survival (PFS) among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic nasopharyngeal carcinoma (NPC), according to a study.

A phase I study has shown the safety and feasibility of treatment with TAC01-HER2, an autologous T-cell product targeting the human epidermal growth factor receptor 2 (HER2), in patients with advanced or metastatic solid tumours.

Camrelizumab combination therapy demonstrates potential benefits in the treatment of patients with triple-negative breast cancer (TNBC), suggests a study.

A family-centred palliative care intervention helps improve the mental well-being and quality of life (QoL) of patients with advanced cancer and their caregivers, a study has shown.